ADI News en New ADI report on the 2nd anniversary of the Global plan on dementia calls for urgent action <p><a href=""><img alt="" src="/sites/default/files/img/Cover%20image.png" style="width: 100px; height: 142px; float: right;" /></a><strong>21 May 2019</strong>&nbsp;&ndash; A new report has been published by ADI to mark the 2nd anniversary of the adoption of the World Health Organization (WHO)&nbsp;<em>Global plan on the public health response to dementia 2017-2025</em>.</p> <!--break--> <p><em><a href="">From Plan to Impact II: the urgent need for action</a></em>&nbsp;will be launched at a side event to the 72nd World Health Assembly on the evening of 21 May 2019, featuring a panel of high-level governmental and industry representatives, including experts from Japan, Qatar, WHO and&nbsp;<a href="">Dementia Alliance International</a>.</p> <p>The report contains an update on the progress towards target one of the Global plan, which calls for 146 WHO Member States to develop plans, policies or other frameworks on dementia by 2025, and features case studies on plans adopted and in development around the world. To date, national plans have been developed by only 26 WHO Member States. In the last two years only two countries (Chile and Qatar) have created plans, meaning at the current rate the 2025 target will not be reached.</p> <p>ADI&rsquo;s CEO Paola Barbarino said: <em>&ldquo;Two years on from the commitment made by 194 Member States at the World Health Assembly, the pace of progress is still too slow. World governments must recognise the crisis we&rsquo;re facing now and proactively work to ensure they&rsquo;re prepared for the dementia emergency at a national level.&rdquo; </em></p> <p>In 2017, the WHO adopted the <a href="" target="_blank"><em>Global action plan on the public health response to dementia 2017-2025</em></a> at the 70<sup>th</sup> World Health Assembly. Action areas of the Global plan also include awareness and dementia friendliness, risk reduction, diagnosis and treatment, care and support, information systems, research and innovation.&nbsp;</p> <p>Every three seconds someone in the world develops dementia. ADI urges that every government develops, allocates funding and monitors a plan&nbsp;on dementia, and dedicates attention to the seven action areas of the Global plan.</p> <ul> <li><a href="">Read the full report</a></li> <li><a href="">Read the media release</a></li> </ul> <h5><strong>Where next?</strong></h5> <ul> <li><a href="">From Plan to Impact</a></li> <li><a href="">Global plan on dementia adopted by WHO</a></li> <li><a href="">ADI Publications</a></li> <li><a href="">About dementia</a></li> </ul> Tue, 21 May 2019 13:47:57 +0000 Jenni.McGowan 3685 at Queen Sofía of Spain awarded for becoming Global Ambassador <p><strong>15 May 2019</strong>&nbsp;&ndash; ADI&#39;s Chief Executive Paola Barbarino presented Her Majesty Queen Sof&iacute;a of Spain with an award for becoming ADI&rsquo;s Global Ambassador at the 3rd Dementia Forum X meeting&nbsp;at the Royal Palace of Stockholm.</p> <!--break--> <p>Queen Sof&iacute;a is also Executive President of&nbsp;<a href="">Fundaci&oacute;n Reina Sof&iacute;a</a>&nbsp;and Honorary President of&nbsp;<a href="">Confederaci&oacute;n Espa&ntilde;ola de Familiares de Enfermos de Alzheimer (CEAFA)</a>, the national Alzheimer association and member of ADI in Spain, which is working closely with the Ministry&nbsp;of Health, Consumption and Social Welfare to develop the National Alzheimer&#39;s Plan 2019-2023.&nbsp;</p> <p>The ceremony took place after it was announced last year that&nbsp;Queen Sof&iacute;a would become an Honorary Ambassador of Alzheimer&rsquo;s Disease International (ADI)&nbsp;in recognition of her personal commitment to dementia research and care globally. &nbsp;</p> <p><img alt="" src="/sites/default/files/img/Queen%20Sofia%20new.jpeg" style="margin-left: 25px; margin-right: 25px; width: 640px; height: 476px;" /></p> <p><strong><em>Pictured: Paola Barbarino, ADI&#39;s CEO awarding Her Majesty Queen&nbsp;Sof&iacute;a of Spain for becoming a Global Ambassador.&nbsp;</em></strong></p> <p>Paola was delighted to present Queen&nbsp;Sof&iacute;a with the award, stating:&nbsp;<em>&ldquo;We are deeply honoured by Her Majesty&rsquo;s acceptance of this role. Queen Sofia&rsquo;s committment to dementia over the years has been a crucial factor in raising awareness and combating stigma and we look forward to continue our work in this direction strengthened by Her Majesty&rsquo;s patronage&rdquo;.</em></p> <p>The support of Global Ambassadors is important to ensure that collaborative, global action is taken to achieve the targets of the&nbsp;<a href="">WHO&rsquo;s global action plan on the public health response to dementia</a>, and to support the global transformation of awareness for people living with dementia and their care partners everywhere.</p> <h5>Where next?</h5> <ul> <li><a href="">Governance</a></li> <li><a href="">About dementia</a></li> <li><a href="">Confederaci&oacute;n Espa&ntilde;ola de Familiares de Enfermos de Alzheimer (CEAFA)</a></li> <li><a href="">Dementia Forum X</a></li> </ul> Wed, 15 May 2019 11:23:12 +0000 Annie.Bliss 3682 at ADI, GADAA and Alzheimer's Pakistan launch report on Dementia in Humanitarian Settings <p><strong>9 May 2019</strong> &ndash;&nbsp;A pioneering new report by ADI, The Global Alzheimer&rsquo;s &amp; Dementia Action Alliance (GADAA) and Alzheimer&#39;s Pakistan has revealed that people with dementia are being ignored in times of humanitarian crisis.</p> <!--break--> <p><img alt="" src="/sites/default/files/img/GADAA%20report%20cover.png" style="width: 168px; height: 200px; float: right;" />The report, <a href="/sites/default/files/pdfs/Forgotten%20in%20a%20Crisis_report_2019.pdf"><strong><em>Forgotten in a crisis: Addressing dementia in humanitarian response</em></strong></a>, revealed that&nbsp;although there are guidelines in place to mandate inclusive support for people at-risk in humanitarian settings, they are rarely being implemented for people with dementia and do not currently go far enough to meet their needs.</p> <p>In some of the worst cases, lack of rescue efforts, health services and basic necessities have resulted in death as people with dementia are unwittingly overlooked by aid agencies, and governments fail to plan for some of society&rsquo;s most at-risk citizens.</p> <p>This report&nbsp;contributes to a growing awareness of the need to address disability in humanitarian settings and is the first report to specifically highlight dementia. &nbsp;</p> <p>Paola Barbarino, CEO of Alzheimer&rsquo;s Disease International, said: <em>&ldquo;There are 50 million people living with dementia globally, 60 per cent in low and middle income countries where diagnosis is low and humanitarian emergencies are widespread. These people are currently ignored in emergency response planning. We are calling on all agencies to increase awareness and to adapt strategies, to better recognise the needs of this often hidden group.&rdquo;</em></p> <p>Amy Little, co-author and Executive Lead of GADAA who also leads Alzheimer&rsquo;s Society&rsquo;s international work, added: <em>&ldquo;During humanitarian emergencies, agencies need to work quickly to identify people living with dementia and then to address their support needs. Ahead of a crisis, governments, agencies and civil society need to work together to plan for people living with dementia. The burden of proof should not be about identifying cases of dementia to demonstrate a need for action, but to assume that this population exists &ndash; which it does, in millions.&rdquo; </em>&nbsp;</p> <ul> <li><a href="">Read the media release</a></li> <li><a href="/sites/default/files/pdfs/Forgotten%20in%20a%20Crisis_report_2019.pdf">Download the report</a></li> </ul> Wed, 08 May 2019 23:00:01 +0000 Annie.Bliss 3681 at A new type of dementia identified? <p><b>3 May 2019 -</b>&nbsp;A paper published in the journal Brain (30 April 2019) has identified a brain disorder that appears to mimic the clinical features of Alzheimer&rsquo;s disease. Known as LATE (Limbic-predominant Age-related TDP-43 Encephalopathy) it appears to be linked to the accumulation of a protein, TDP-43, in the brain, while Alzheimer&#39;s disease is more commonly linked to two other brain proteins - amyloid and tau.</p> <!--break--> <p>The authors of the report say that LATE appears to affect the &quot;oldest old&quot;, people over 80, based on work that looked at evidence from thousands of post-mortem results.</p> <p>It raises interesting and challenging questions around diagnosis; how to test people non-invasively and cost effectively. It raises questions around clinical trials and ultimately it will pose questions around treatment options. It is not yet known how many people may have LATE.</p> <p>Dr Alireza Atri, Co-Chair of ADI&rsquo;s Medical &amp; Scientific Advisory Panel, said &quot;This timely consensus workgroup report supports an accumulating evidence-base regarding the importance of determining the independent and inter-related contributions of multiple disease pathways to late-life cognitive decline, impairment and dementia. Future treatments are unlikely to be highly effective unless we learn to more accurately diagnose and use combinations of targeted and personalized approaches to impact all the factors relating to aging, Alzheimer&#39;s disease, and non-Alzheimer&#39;s disease that often combine to cause symptoms in an older individual.&quot;&nbsp;</p> <p>Kate Swaffer, Chair and CEO, Dementia Alliance International said, &quot;This latest research is of great interest to Dementia Alliance International members, especially as many are regularly challenged about the validity of their own diagnoses, especially those living with younger onset dementia. Whilst it relates to older adults with cognitive decline, the more research that supports a more accurate diagnosis of Alzheimer&#39;s disease, will not only lead to more targeted research and hopefully treatments, but will ultimately be reflected in increasing the accuracy of all dementia diagnoses.&quot;</p> <p>To hear more about LATE and to ask questions of our expert panel <a href="">join ADI&rsquo;s FREE research webinar </a>on<strong> Friday 10 May</strong>.&nbsp;</p> <p><img alt="" src="/sites/default/files/img/research%20image-%20neurone.jpg" style="margin: 25px 50px; width: 524px; height: 480px;" /></p> <p><strong>Dr Atri offers a more detailed review of the report below:</strong></p> <p>Never Too LATE to Improve Our Understanding of Conditions and Diseases that Cause Late-Life Cognitive Impairment and Dementia</p> <p>This report, a Workgroup diagnostic guideline paper (Nelson et al. Brain 2019) , provides an important pathway to advance understanding and research on conditions and diseases that impact late-life cognitive decline and dementia syndromes (changes in cognitive abilities sufficient to impact daily functions and behavior). This important evidence- and expert-based research formalizes terminology and provides consensus guidelines for diagnostic and staging criteria for a protein-related disease (aka. proteinopathy) due to TDP-43 protein that has been, in the last 15-25 years, increasingly reported to produce Alzheimer&rsquo;s disease (AD)-like dementia symptoms by causing conditions such as Hippocampal Sclerosis and Age-related TDP-proteinopathy. The Workgroup coined the term LATE (Limbic-predominant Age-related TDP-43 Encephalopathy) for such TDP-43 proteinopathy conditions that cause cognitive impairment and dementia (CID) and provides evidence to support that LATE is a disease that may cause or contribute to CID in 15-20% of older-old individuals (those older than 80-85 years of age).</p> <p>In the last two decades, multiple lines of evidence, particularly from long-term brain donation autopsy research studies, have made it increasing clear that cognitive and behavioral changes and symptoms in older-old individuals, that are sufficient to produce CID syndromes, are due to a confluence of multiple conditions that impact cognitive functions. While brain changes due to AD, defined by the presence of amyloid-beta protein plaques and tau-protein tangles, are commonly observed in autopsy studies, there is likely more often an interaction of several conditions, such as vascular brain injury (VBI), and other proteinopathies such as those caused by alpha-synuclein proteinopathy (Lewy Body Disease) and TDP-43 proteinopathy (LATE), that combine to produce symptoms in the older-old.</p> <p>Therefore, in a substantial number of older-old individuals, what can appear in the clinic to be very similar to CID symptoms due to Alzheimer&rsquo;s can be caused by LATE or by the combined effects of LATE with AD and related conditions. As well as sharing common symptoms with typical dementia due to AD, particularly problems with learning and forming new memories, the report also outlines how LATE shares some common risks with AD (such as age and genetic features) and findings on brain imaging, such as shrinkage of hippocampus and medial temporal lobes. The Workgroup&rsquo;s formalized recommendations and diagnostic criteria are important to promote awareness in the medical, scientific, and patient communities and in the general public. The guidelines are also crucial to stimulate interdisciplinary research to better diagnosis and treat LATE during life, including by use of biomarkers to exclude AD (e.g. spinal fluid or PET scan signatures related to AD), and the development of specific LATE-related biomarkers, and prevention and treatment approaches. It&rsquo;s never too late to learn and be smarter and wiser about investigating multi-factorial approaches to combat the complex and inter-related conditions and diseases that causes CID.</p> <p>&nbsp;</p> <h5>Where next?</h5> <ul> <li><a href="">Global webinars on research participation</a></li> <li><a href="">About Dementia</a></li> </ul> Fri, 03 May 2019 12:00:00 +0000 Jenni.McGowan 3679 at ADI invites you to their side event at the 72nd World Health Assembly <p><b>1 May 2019</b> - Alzheimer&#39;s Disease International&nbsp;(ADI) is delighted to invite you to a side event at the 72nd World Health Assembly, moderated by Chief Executive Paola Barbarino.</p> <p>The 72nd World Health Assembly in May marks the second anniversary of the adoption of the&nbsp;<a href=""><em>Global action plan&nbsp;on the public health response to dementia 2017-2025</em></a>.&nbsp;We are delighted to invite you to attend a special side event:&nbsp;<em><strong>Why we all need to do more: Examining the seven action areas of the Global action plan on dementia.</strong></em>&nbsp;The event will coincide with the launch of our report&nbsp;<a href="">From Plan to Impact</a>, which will provide an update on progress towards the targets of the Global Plan.</p> <p><strong><img alt="" src="/sites/default/files/img/WHA%20side%20event.jpg" style="width: 400px; height: 300px; margin-left: 150px; margin-right: 150px;" /></strong></p> <p><strong>Pictured:&nbsp;Our side event in 2018; Paola Barbarino chairing a panel with Government&nbsp;representatives from Australia,&nbsp;Japan,&nbsp;the Netherlands, the UK;&nbsp;the (former) Director of Mental Health at WHO and Kate Swaffer, CEO of&nbsp;Dementia&nbsp;Alliance International (DAI).</strong></p> <p>This year&#39;s&nbsp;event will feature an expert panel including D&eacute;vora Kestel, Director, Mental Health and Substance Abuse, WHO; Kate Swaffer, Chair, CEO and Co-founder of&nbsp;<a href="">Dementia Alliance International (DAI)</a>;&nbsp;government representatives and sector specialists. Final line up to be confirmed.</p> <p>We believe that this event will be of great importance to those attending the Assembly from around the world and will be an additional opportunity to strengthen implementation of the Global plan, and the development of national plans on dementia globally.&nbsp;<strong>Please let us know if you are able to attend by <a href="">signing up on-line via Eventbrite</a>.</strong></p> <p><em>Please join us for a drinks reception and canapés from 18:15. The panel presentations and discussion will begin at 18:45.</em></p> <ul> <li><a href="">Register for the event</a></li> <li><a href="">From Plan to Impact</a></li> <li><a href="">Dementia plans</a></li> </ul> Wed, 01 May 2019 16:12:35 +0000 Annie.Bliss 3678 at Survey on attitudes around dementia now open <p><strong>15 April 2019 </strong>&ndash; ADI&#39;s survey on attitudes around dementia is now <strong>open </strong>and we want to hear what YOU think.&nbsp;The survey will form the basis for the <a href="">World Alzheimer Report 2019</a>, to be released in September. It will only take around&nbsp;10 minutes&nbsp;of your time but completing it will benefit people with dementia all over the world. <a href="">[Read more]</a>&nbsp;</p> Sun, 14 Apr 2019 23:00:00 +0000 Jenni.McGowan 3677 at Queen Silvia of Sweden awarded for becoming Global Ambassador <p><strong>3 April 2019</strong> &ndash; ADI&#39;s Chief Executive Paola Barbarino presented Her Majesty Queen Silvia of Sweden with an award for becoming ADI&rsquo;s Global Ambassador at the Jubilee event for the <a href="">Queen Silvia Nursing Award</a> at the Royal Palace of Stockholm.</p> <!--break--> <p>The award is a scholarship for nursing students in Sweden, Finland, Poland and Germany founded in 2013 as a gift to to support innovations in elderly care. It was gifted to Her Majesty Queen Silvia of Sweden in 2013, and requires that the idea improves the care of elderly and/or dementia patients.</p> <p>The ceremony took place four months after it was announced that <a href="/news/queen-silvia-of-sweden-becomes-adi-ambassador">Queen Silvia would become an Honorary Ambassador of Alzheimer&rsquo;s Disease International (ADI) </a>in recognition of her personal commitment to work surrounding elderly and end of life care, and specifically dementia - in large part through the Queen Silvia Nursing Award scheme. She was also responsible for initiating a dementia care training programme for hospital personnel in Sweden by the foundation <em>Stiftelsen Silviahemmet</em>.</p> <p>Paola delivered the key note lecture at the event, stating: <em>&ldquo;There are countries in the world that say there is no problem regarding dementia. We hope to reach out to these countries and let the people speak to combine results, which help understand advocacy and outreach for those impacted by dementia. We need more voices and dementia to be taken seriously. Help us raise awareness. Let us advocate more loudly. Everyone is an ambassador for the dementia movement.&rdquo;</em></p> <p><img alt="" src="/sites/default/files/img/Queen%20Silvia%20award_April%202019.jpeg" style="width: 640px; height: 427px; margin-left: 30px; margin-right: 30px;" /></p> <p><em>Above: Paola Barbarino, ADI&#39;s CEO awarding Her Majesty Queen Silvia of Sweden for becoming a Global Ambassador. Official photograph by Yanan Li.</em></p> <p><a href="/news/president-of-costa-rica-becomes-adi-ambassador">Luis Guillermo Sol&iacute;s Rivera</a>, Former President of Costa Rica and <a href="/news/queen-sofia-of-spain-becomes-adi-ambassador">Her Majesty Queen Sofia of Spain</a> are also Honorary Ambassadors of ADI.</p> <p>The support of Global Ambassadors is important to ensure that collaborative, global action is taken to achieve the targets of the <a href="">WHO&rsquo;s global action plan on the public health response to dementia</a>, and to support the global transformation of awareness for people living with dementia and their care partners everywhere.</p> <p>ADI has a strategic partnership with <a href="">Swedish Care International</a> and a long-standing collaboration with the <a href="">Karolinska Institutet</a>.</p> <h5>Where next?</h5> <ul> <li><a href="/elected-board">Governance</a></li> <li><a href="/about-dementia">About dementia</a></li> </ul> Mon, 08 Apr 2019 13:30:00 +0000 Annie.Bliss 3676 at Biogen and Eisai remain committed after discontinuation of ENGAGE and EMERGE programmes <p><strong>22 March 2019&nbsp;</strong>&ndash;&nbsp;Pharmaceutical companies Biogen and Eisai have announced the discontinuation of two Phase 3 trials of aducanumab. The decision came after analysis by an independent monitoring committee indicated the trials were unlikely to succeed. Biogen and Eisai will continue to investigate other treatments for Alzheimer&rsquo;s disease, including anti-amyloid treatment BAN2401.</p> <!--break--> <p>Michel Vounatsos, Chief Executive Officer at Biogen, said:</p> <p style="margin-left:1.0cm;">&ldquo;This disappointing news confirms the complexity of treating Alzheimer&rsquo;s disease and the need to further advance knowledge in neuroscience.&nbsp; We are incredibly grateful to all the Alzheimer&rsquo;s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research. Biogen&rsquo;s history has been based on pioneering innovation, learning from successes and setbacks. [&hellip;] We will continue advancing our pipeline of potential therapies in Alzheimer&rsquo;s disease and innovative medicines.&rdquo;</p> <p>Alzheimer&rsquo;s disease is the most common form of dementia, the collective term for a range of degenerative neurological conditions that affect memory, thinking, behaviour and emotion. There is no cure for dementia and has been no new treatment for the symptoms of dementia since 2002.</p> <p>ADI is reassured that Biogen and Eisai remain committed to the field and will continue with other research into treatment for Alzheimer&rsquo;s disease and other dementias. Detailed data from the ENGAGE and EMERGE studies will be presented at future medical meetings to inform ongoing research.</p> <p>Paola Barbarino, Chief Executive Officer of ADI, said:</p> <p style="margin-left:1.0cm;">&ldquo;Although we are of course disappointed by the news from these particular trials, we must consider what has been learned and continue to do everything we can to support those affected by dementia around the world. We are reassured by the ongoing commitment of Biogen and Eisai to develop treatments and diagnosis methods to improve the lives of people living with dementia and their families.&rdquo;</p> <p>More investment is needed to support research on dementia across all key areas: basic science, care improvements, prevention and risk reduction, drug development and public health. Read more in the&nbsp;<a href="">World Alzheimer Report 2018</a>&nbsp;and join our&nbsp;<a href="">Global webinars on research participation</a>.</p> <ul> <li><a href="">Read Biogen&rsquo;s press release</a></li> <li><a href="">Read Eisai&rsquo;s press release</a></li> </ul> Fri, 22 Mar 2019 16:13:06 +0000 Jenni.McGowan 3675 at Global Perspective Newsletter for February 2019 <p><img alt="" src="/sites/default/files/img/Front%20page%20-%20screenshot_0.jpg" style="width: 80px; height: 113px; float: right;" />The February 2019 edition of our Global Perspective Newsletter is now available. Read the latest&nbsp;news from ADI, our partners and member associations, including updates from&nbsp;the WHO Executive Board; the Korean National Institute (KNID)&#39;s symposium; Dementia Alliance International, and much more.&nbsp;<a href="">[read it now]</a></p> <!--break--> Fri, 01 Mar 2019 14:18:26 +0000 Jenni.McGowan 3672 at El Informe Mundial sobre el Alzheimer 2018 ya está disponible en español <p><strong>31 de ener</strong><a href=""><img alt="" src="/sites/default/files/img/WAR%20Spanish%20cover.png" style="margin: 5px; float: right; width: 120px; height: 170px;" /></a><strong>o de 2019</strong> &ndash; El Informe Mundial sobre el Alzheimer 2018&nbsp;ya est&aacute; disponible en espa&ntilde;ol en nuestro sitio web. El informe aborda cuestiones claves en la investigaci&oacute;n de la demencia, sobre ciencia b&aacute;sica, diagn&oacute;stico, descubrimiento de f&aacute;rmacos, reducci&oacute;n de riesgos, epidemiolog&iacute;a y cuidados. Descubre lo que tienen que decir los principales investigadores de la demencia a nivel mundial.&nbsp;<a href="/research/world-report-2018">[Lea m&aacute;s]</a></p> <!--break--> <h3><strong>World Alzheimer Report 2018 now available in Spanish</strong></h3> <p><strong>31 January 2019</strong>&nbsp;&ndash;&nbsp;The World Alzheimer Report 2018 is now available to download in Spanish. The report addresses key questions in dementia research, on&nbsp;basic science, diagnosis, drug discovery, risk reduction, epidemiology and care. Find out what the leading lights in dementia research globally have to say.&nbsp;<a href="/research/world-report-2018">[read more]</a></p> <div class="field field-type-filefield field-field-news-fp-image"> <div class="field-label">Front Page Image:&nbsp;</div> <div class="field-items"> <div class="field-item odd"> <img class="imagefield imagefield-field_news_fp_image" width="634" height="322" alt="" src="" /> </div> </div> </div> Thu, 31 Jan 2019 13:23:30 +0000 Jenni.McGowan 3671 at